Every Form 4 that Coya Therapeutics, Inc. (COYA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow COYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COYA filings page.
Coya Therapeutics, Inc. director Mark H. Pavao received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $4.53 per share, expire on April 9, 2036, and will vest 100% on the first anniversary of the grant date, subject to continuous service.
Coya Therapeutics reported that its Chief Financial Officer, David S. Snyder, received a grant of stock options on January 22, 2026. The award covers 140,041 stock options, each giving the right to buy one share of common stock at an exercise price of $4.73 per share.
The options vest in monthly installments over 36 months, as long as the executive continues to serve through each vesting date. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
Coya Therapeutics, Inc. reported that Chief Medical Officer Fred Grossman received a grant of stock options to purchase 140,041 shares of common stock at an exercise price of $4.73 per share. The options were awarded at no cash cost at grant and are held directly. Subject to continuous service, the shares underlying the option vest in monthly installments over the next 36 months. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended effective November 17, 2022.
Coya Therapeutics, Inc. reported that Executive Chairman Howard Berman received a stock option grant on 01/22/2026. The option gives him the right to buy 15,257 shares of common stock at an exercise price of $4.73 per share.
These options vest in monthly installments over the next 36 months, as long as he remains in continuous service through each vesting date. The filing also states that if there is a change in control of the company, all unvested shares under this option will vest and the option will become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended in November 2022.
Coya Therapeutics, Inc. reported a new equity award to its Chief Executive Officer, Swaminathan Arun. On January 22, 2026, he received a stock option covering 293,983 shares of common stock with an exercise price of $4.73 per share.
These options were granted at a price of $0 for the derivative itself and are held directly. The shares underlying the option vest in monthly installments over 36 months, conditioned on continued service. If there is a change in control of Coya Therapeutics, all unvested shares under this option will vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
Coya Therapeutics director Anabella Villalobos received a grant of stock options covering 10,000 shares of common stock. The options were granted on January 2, 2026 with an exercise price of $5.65 per share and no cost to receive the award. The filing reports that Villalobos now beneficially owns 10,000 derivative securities directly.
According to the vesting terms, 100% of the option will vest on the first anniversary of the grant date, as long as continuous service is maintained. The options are scheduled to expire on January 2, 2036 if not exercised.
Coya Therapeutics, Inc. reported that director Wilbur L. Ross Jr. received a new stock option award. On January 2, 2026, he was granted a stock option to buy 10,000 shares of Coya common stock at an exercise price of $5.65 per share. The option was granted at no cost and is held directly.
Subject to his continuous service, 100% of the option will vest on the first anniversary of the grant date, meaning it becomes fully exercisable after one year. The option is scheduled to expire on January 2, 2036 if not exercised. Following this grant, he beneficially owns 10,000 derivative securities in the form of this option.
Coya Therapeutics, Inc. director Lee Ann reported receiving a stock option grant. On January 2, 2026, she was granted a stock option to buy 10,000 shares of common stock with an exercise price of $5.65 per share.
The option was granted for no cash cost and is held directly. Subject to continuous service, 100% of the option vests on the first anniversary of the grant date. The option becomes exercisable on January 2, 2027 and is scheduled to expire on January 2, 2036. Following this grant, Lee Ann beneficially owns 10,000 derivative securities in the form of this option.